Shares of Supernus Pharmaceuticals fell over 13% in trading on February 19, after the company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo. This outcome comes as a surprise to investors, given the company's previous optimism surrounding the drug’s potential. Block & Leviton is investigating the company's prior disclosures.
Contact our attorneys for a no-cost case evaluation.